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Objective: To compare adherence with statin therapy in patients switching to single-pill amlodipine 
besylate/atorvastatin calcium with patients adding a separate statin to their amlodipine 
regimen.
Methods: We identified hypertensive patients prescribed amlodipine who switched to 
amlodipine/atorvastatin (switch) or added a statin to their amlodipine regimen (add-on) from 
July 2004 to June 2007. Propensity score matching (1 switch:3 add-on) was applied based on 
‘nearest neighbor’ approach. The primary adherence measure was patients with proportion of 
days covered (PDC) 0.80 at 180 days; secondary measures included mean PDC and persistence. 
A sensitivity analysis was performed, accounting for total statin/amlodipine exposure.
Results: Among 4556 matched patients (n = 1139 switch; n = 3417 add-on), mean age was 
53.9 years and 52.1% were male. After 180 days, adherence with statin therapy was higher 
for the switch vs add-on cohort (50.8% vs 44.3%; P  0.001). After adjusting for pre-index 
amlodipine adherence, the switch cohort was more likely to be adherent than the add-on cohort 
(odds ratio: 1.64 [95% confidence interval: 1.42 to 1.89]). Persistence was higher in the switch 
than the add-on cohort (127.6 vs 117 days; P  0.001).
Conclusion: Hypertensive patients taking amlodipine who initiated statin therapy via single-pill 
amlodipine/atorvastatin were more likely to remain adherent to their statin than patients adding 
a separate statin to their antihypertensive regimen.
Keywords: adherence, amlodipine, atorvastatin, cardiovascular disease, persistence, single-pill
Introduction
Cardiovascular disease (CVD) remains the leading cause of death in developed 
countries, and accounts for more than one-third of deaths in the United States.1 
The co-occurrence of risk factors for CVD – including hypertension, dyslipidemia, 
diabetes, current smoking, and being overweight – is associated with a markedly 
increased risk of cardiovascular events.2,3 Of the numerous factors that contribute to 
cardiovascular risk, hypertension and dyslipidemia are highly prevalent either alone 
or in combination.4–6 Indeed, hypertension rarely occurs in isolation from other risk 
factors for CVD.6,7
The beneficial reduction in the risk of cardiovascular events provided by antihy-
pertensive and lipid-lowering therapy has been confirmed through numerous clinical 
trials and meta-analyses.8–12 However, attainment of guideline-recommended blood 
pressure (BP) and low-density lipoprotein cholesterol (LDL-C) goals in real-world 
clinical practice is low,6,7,13 despite the availability of effective treatments. The 2008 
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Chapman et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
concluded that individuals at high risk of CVD are not being 
managed effectively (in-line with 2003 European guidelines14) 
as only 26% had controlled BP (140/90 mmHg) and only 
31% had LDL-C  2.5 mmol/L (96 mg/dL).15 These data 
are in line with a 2006 analysis of the US National Health 
and Nutrition Examination Survey (NHANES) database 
which reported that 47% of the surveyed population had 
hypercholesterolemia, and only 11% of these had their lipids 
controlled (LDL-C  120 mg/dL).6 Furthermore, 30% had 
hypertension, but only 41% of hypertensive patients had their 
BP controlled (140/90 mmHg).6
Inadequate adherence to antihypertensive and lipid-
lowering medications likely contributes to this failure to attain 
BP and/or LDL-C goals, as poor adherence is associated with 
suboptimal clinical outcomes.16–20 For example, in a study 
of a large managed care cohort, both therapy intensification 
and medication adherence were important components for 
achieving recommended BP goals.18
When examining the outcomes from a retrospective study 
of patients with comorbid hypertension and dyslipidemia who 
initiated therapy with separate prescriptions for antihyper-
tensive and lipid-lowering medications, we found that while 
58% of patients were adherent with their antihypertensive 
therapy at 6 months, only 43% were adherent with their 
lipid-lowering medication.21 Thus, there may be potential 
for improving adherence with concurrent antihypertensive 
and lipid-lowering therapies simply by increasing adher-
ence with lipid-lowering therapy to levels observed with 
antihypertensives.
Potential strategies for improving adherence with therapy 
include simplification of a drug regimen with the use of 
single-pill combination therapies, which reduces a patient’s 
pill burden and also synchronizes the initiation of concomitant 
therapies.22–25 Single-pill amlodipine/atorvastatin is the first 
fixed-dose combination that includes an antihypertensive 
and a statin to treat multiple risk factors for CVD.26–28 The 
single-pill formulation has been shown to improve adherence 
compared with a two-pill regimen in patients without prior 
experience of calcium channel blocker or statin therapy.29 
However, it is not currently known whether the use of 
single-pill therapy can help to increase patients’ adherence 
with statin therapy to the levels of adherence observed 
with antihypertensives. We therefore sought to determine 
whether adherence with new statin therapy in patients 
already receiving amlodipine is better among patients who 
switch to single-pill amlodipine/atorvastatin compared with 
patients in whom a separate statin is added on to their existing 
amlodipine therapy.
Methods
study design
We conducted a retrospective cohort study using the 
PharMetrics Patient-Centric Database (Watertown, MA, 
USA), which is a large, nationally representative database 
including US enrollees across approximately 90 US 
health insurance plans. The database is composed of fully 
adjudicated medical and pharmaceutical claims from more 
than 55 million unique patients, and contains over 2 billion 
healthcare transactions, including prescriptions, office 
visits, hospital stays, and diagnostic tests. Patients in the 
database are representative of the national commercially 
insured population on a variety of demographic measures.30 
Treatment in long-term care settings, such as nursing homes 
and hospices, is not included.
We identified adults (aged  18 years) who filled a new 
prescription for either single-pill amlodipine/atorvastatin or a 
statin during a 36-month period (July 1, 2004 to June 30, 2007); 
the prescription fill date of the initial amlodipine/atorvastatin or 
statin prescription was considered the index date. Patients were 
excluded who had: a single-pill amlodipine/atorvastatin or 
statin prescription during the 360 days prior to the index date; 
no evidence of amlodipine use from 360 days pre-index date 
through 30 days post-index date; an amlodipine prescription 
on the same day as the single-pill amlodipine/atorvastatin 
prescription; or no evidence of a diagnosis of hypertension 
pre-index through the index date. Patients were also excluded 
if they were aged  65 years and not enrolled in a Medicare 
Risk plan (complete claims histories may not be available for 
patients aged  65 years without Medicare Risk coverage due 
to benefit coordination issues with other payers). All patients 
were continuously enrolled for 360 days before and 180 days 
after the index date and had either a pre-index amlodipine 
prescription with at least one day’s supply that spanned 
over the index date or an amlodipine prescription in both 
the pre- and post-index periods. Patients were followed for 
180 days post-index date to maximize data availability and 
increase the number of patients eligible for inclusion.
study population
Patients meeting the study criteria were divided into two 
cohorts: (1) amlodipine/atorvastatin switch cohort: patients 
on amlodipine who switched to single-pill amlodipine/
atorvastatin, and (2) statin add-on cohort: patients on 
amlodipine who added statin therapy.
Because we hypothesized that disease severity and other 
unobserved patient characteristics could be associated with 
medication choice, patients were matched in a 1:3 ratio Patient Preference and Adherence 2009:3 267
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(single-pill switch: statin add-on) based on propensity score 
weighting. Logistic regression was used to calculate the 
propensity score as the likelihood of being in the single-pill 
atorvastatin/amlodipine cohort vs the statin add-on cohort based 
on pre-index variables. Variables included in the propensity 
score model were: age, gender, plan type, payer type, geographic 
region, total number of pre-index antihypertensive prescription 
classes, and comorbidity index score (Dartmouth-Manitoba 
adaptation of the Charlson comorbidity index).31 Each patient 
was calculated a unique probability score of being in a given 
medication cohort, which was used to match patients from each 
cohort. Patients were matched based on a ‘nearest neighbor’ 
approach, defined by a minimal difference (eg, ±0.001) in the 
fitted probability of amlodipine/atorvastatin use.32,33
Adherence
Measures of adherence, including the proportion of patients 
achieving adherence and persistence, were compared between 
the amlodipine/atorvastatin switch and statin add-on cohorts.
Adherence was calculated as the proportion of days 
covered (PDC) during the 180-day follow-up period. 
PDC is the proportion of days in the study period that the 
treatment regimen is available to the patient, as observed 
from pharmacy claims data and medical records. In scenarios 
where an overlap in medication refills existed, unique 
days with drug on hand were counted. Days supply falling 
beyond the 180-day study period was truncated and not 
used in the PDC calculation. For the proportion of patients 
achieving adherence, patients were considered ‘adherent’ if 
PDC  0.80.16,19,21,29,34–36 Patients were considered ‘persistent’ 
for the number of consecutive days from therapy initiation 
to the first 30-day gap in therapy.
Since patients could switch to and from different statins or 
combinations of statins and amlodipine, a sensitivity analysis 
was conducted on the total amlodipine and statin exposure 
in the post-index period. Under this analysis, any use of 
either amlodipine or a statin in either cohort was considered 
‘adherent’ (eg, patients from the statin add-on cohort who 
switched to single-pill amlodipine/atorvastatin were still 
credited as receiving amlodipine and statin prescriptions and 
vice versa). Adherence measures for amlodipine and statin 
were considered separately and compared for each cohort.
statistical analyses
The primary analysis compared the likelihood of achieving 
adherence (PDC  0.80) to statin therapy using generalized 
linear models for each of the matched cohorts, controlling 
for prior amlodipine adherence and history of CVD.
Comparisons of adherence rates and proportions 
achieving adherence used Wilcoxon rank-sum tests for 
continuous variables and chi-square tests for categorical 
variables. Kaplan-Meier analysis was carried out to 
estimate the proportion of patients who remained persistent 
with the index drug by cohort. The probability of remaining 
persistent with therapy in each interval was calculated 
based on the number of patients still being followed who 
had not been excluded through each interval. Patients 
were censored at either the point of discontinuation of 
the index medication or the point of eligibility loss from 
the Health Plan database, whichever occurred first. Data 
extractions and statistical analyses were performed using 
SAS® software versions 8.2 and 9.1.3 (SAS Institute Inc., 
Cary, NC, USA).
Results
Patient characteristics
Of the 1,489,484 patients with an initial amlodipine/
atorvastatin or statin claim, 13,343 met all criteria for 
inclusion. Among these, 1139 patients from the amlodipine/
atorvastatin switch cohort were matched in a 1:3 ratio 
with statin add-on patients (1139 amlodipine/atorvastatin 
switch and 3417 statin add-on) using the propensity score 
matching method, to yield a final sample of 4,556 patients. 
Baseline characteristics for the pre-match and post-match 
cohorts are shown in Table 1. After matching, patient 
characteristics were similar in both groups; mean age was 
53.9 years in both cohorts and approximately half were 
male (Table 1).
The overall severity of illness (measured using the 
Charlson Comorbidity Index) was similar between groups, 
although a slightly higher proportion of patients in the 
amlodipine/atorvastatin switch cohort was classified as 
having primary CVD prevention status (ie, no history of 
CV events) than in the statin add-on cohort (87.4% vs 
82.1%; P  0.001) (Table 1). Significantly fewer patients 
in the amlodipine/atorvastatin switch cohort than in the 
statin add-on cohort had a history of angina (4.7% vs 8.0%, 
respectively; P  0.001) and a history of revascularization 
procedures (1.4% vs 4.5%; P  0.001) at index. In addition, 
the differences in the incidence of comorbid cancer 
and prior MI between groups approached significance 
(p = 0.062 and 0.073, respectively). The proportion of 
patients with pre-index amlodipine adherence (PDC  0.80) 
was significantly lower in the amlodipine/atorvastatin 
switch cohort than in the statin add-on cohort (52.4% 
vs 71.4%; P  0.001). The mean number of pre-index Patient Preference and Adherence 2009:3 268
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Table 1 Characteristics for pre- and post-match patient cohorts
Characteristics Pre-match  Post-match
Amlodipine/
atorvastatin 
switch 
(n = 1177)
Statin add-on 
(n = 12,166)
Amlodipine/
atorvastatin 
switch 
(n = 1139)
Statin add-on 
(n = 3417)
P-value 
between 
matched 
cohorts
  Agea, years 53.5 ± 8.9 56.1 ± 10.2 53.9 ± 8.7 53.9 ± 8.1 0.498
  gendera, male 631 (53.6) 6257 (51.4) 614 (53.9) 1760 (51.5) 0.160
geographic regiona 0.509
  northeast 407 (34.6) 3968 (32.6) 401 (35.2) 1282 (37.5)
  Midwest 281 (23.9) 4591 (37.7) 281 (24.7) 823 (24.1)
  south 465 (39.5) 3264 (26.8) 433 (38.0) 1234 (36.1)
  West 24 (2.0) 343 (2.8) 24 (2.1) 78 (2.3)
CVD status
  Primary preventionb 1032 (87.7) 9445 (77.6) 995 (87.4) 2804 (82.1) 0.001
Plan typea 0.439
  health maintenance organization 264 (22.4) 3941 (32.4) 264 (23.2) 802 (23.5)
  Preferred provider organization 635 (54.0) 5168 (42.5) 598 (52.5) 1730 (50.6)
  Point of service 180 (15.3) 2054 (16.9) 179 (15.7) 527 (15.4)
  indemnity plan 79 (6.7) 771 (6.3) 79 (6.9) 294 (8.6)
  Unknown 19 (1.6) 232 (1.9) 19 (1.7) 64 (1.9)
Payer typea 0.290
  Commercial 1074 (91.2) 10,076 (82.8) 1036 (91.0) 3104 (90.8)
  Medicaid 1 (0.1) 119 (1.0) 1 (0.1) 3 (0.1)
  Medicare risk 47 (4.0) 1258 (10.3) 47 (4.1) 108 (3.2)
  self-insured 49 (4.2) 662 (5.4) 49 (4.3) 188 (5.5)
  Unknown 6 (0.5) 51 (0.4) 6 (0.5) 14 (0.4)
  Charlson comorbidity indexa 0.9 ± 1.4 1.2 ± 1.6 0.9 ± 1.4 0.9 ± 1.3 0.867
    number of pre-index Ah drug 
classesa
0.7 ± 0.8 0.8 ± 0.8 0.7 ± 0.8 0.7 ± 0.7 0.777
Co-morbidities of interest
  Cancer 70 (5.9) 874 (7.2) 70 (6.1) 162 (4.7) 0.062
  Diabetes mellitus 311 (26.4) 3854 (31.7) 310 (27.2) 892 (26.1) 0.461
  Dyslipidemia 879 (74.7) 8661 (71.2) 851 (74.7) 2459 (72.0) 0.071
  Obesity 94 (8.0) 1083 (8.9) 92 (8.1) 262 (7.7) 0.655
  Chronic renal failure 47 (4.0) 772 (6.3) 46 (4.0) 125 (3.7) 0.559
  heart failurec 36 (3.1) 783 (6.4) 36 (3.2) 142 (4.2) 0.133
  Myocardial infarction 24 (2.0) 548 (4.5) 24 (2.1) 107 (3.1) 0.073
  Angina (unstable and pectoris) 55 (4.7) 1105 (9.1) 54 (4.7) 272 (8.0) 0.001
  Other ischemic heart disease 8 (0.7) 114 (0.9) 8 (0.7) 23 (0.7) 0.917
    ischemic stroke/transient 
ischemic attack
65 (5.5) 1094 (9.0) 65 (5.7) 232 (6.8) 0.200
  Peripheral vascular disease 57 (4.8) 760 (6.2) 57 (5.0) 153 (4.5) 0.463
  COPD 55 (4.7) 800 (6.6) 54 (4.7) 168 (4.9) 0.812
Procedures of interest
  Revascularization 16 (1.4) 588 (4.8) 16 (1.4) 153 (4.5) 0.001
  endarterectomy 2 (0.2) 24 (0.2) 2 (0.2) 6 (0.2) 1.000
    Pre-index amlodipine 
prescriptions
– – 5.2 ± 3.6 5.5 ± 3.8 0.059
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antihypertensive classes was similar between the two 
matched patient cohorts.
Proportion of patients achieving 
adherence
At 180 days post-index follow-up, the proportion of patients 
achieving adherence (PDC  0.80) with statin therapy was 
significantly higher for the amlodipine/atorvastatin switch 
cohort compared with the statin add-on cohort (50.8% vs 
44.3% P  0.001; Table 2).
In multivariable logistic regression modeling, patients 
who switched to amlodipine/atorvastatin had 1.64-times 
greater odds of achieving adherence with their statin 
therapy than those receiving a statin as add-on therapy 
(P  0.001; Figure 1), after adjusting for pre-index adherence 
(PDC  0.80) with amlodipine and CVD prevention status 
(primary vs secondary). As expected, patients with pre-index 
amlodipine adherence were significantly more likely to 
achieve post-index adherence with statin therapy than those 
defined as non-adherent (odds ratio [OR] = 2.95, 95% 
confidence interval [CI] = 2.57, 3.37; P  0.001; Figure 1). 
Among all patients, 50.8% of the switch cohort and 44.3% 
of the statin add-on cohort were adherent (PDC  0.80) at 
180-day follow-up (Table 2).
Persistence with therapy
Persistence with statin therapy in the 180-day post-index 
period was superior in the amlodipine/atorvastatin switch 
cohort vs the statin add-on cohort (Figure 2). The mean 
number of days patients were persistent with therapy in 
the amlodipine/atorvastatin switch cohort was 127.6 days 
compared with 116.9 days in the statin add-on cohort 
(P  0.001) (Table 2). Similarly, when restricted to those 
patients with 2 prescriptions, the mean persistence was 
significantly better among patients in the amlodipine/
atorvastatin switch cohort compared with the statin add-on 
cohort (143.0 vs 135.0 days; P  0.001).
Overall statin and amlodipine exposure
When a sensitivity analysis was conducted to assess any 
amlodipine use (including amlodipine received as part 
of the single-pill combination or as amlodipine alone) in 
each cohort during the study period, more patients in the 
amlodipine/atorvastatin switch cohort achieved post-index 
adherence (PDC  0.80) for any amlodipine use compared 
with the statin add-on cohort (59.5% vs 42.5%; P  0.001) 
(Table 3). Among amlodipine users filling 2 prescriptions, 
mean PDC for amlodipine use in the amlodipine/atorvastatin 
switch cohort was higher vs the statin add-on cohort (0.80 vs 
0.75; P  0.001).
Similarly, when any statin use was assessed (including 
statin therapy received as part of the single-pill combination 
or as any statin alone) during the study period, more 
patients in the switch cohort achieved post-index adherence 
(PDC  0.80) for any statin compared with the statin add-on 
cohort (53.8% vs 45.0%; P  0.001) (Table 3). Mean PDC 
for any statin was also higher for the switch cohort compared 
with the add-on cohort among patients filling two or more 
prescriptions (0.79 vs 0.75; P  0.003).
Discussion
This study demonstrates that for patients prescribed 
amlodipine, switching to single-pill amlodipine/atorvastatin 
resulted in higher adherence with statin therapy when 
compared to adding a separate statin to their current 
antihypertensive regimen. Furthermore, the adherence benefit 
in the amlodipine/atorvastatin switch cohort remained even 
Table 1 (Continued)
Characteristics Pre-match  Post-match
Amlodipine/ 
atorvastatin 
switch 
(n = 1177)
Statin add-on 
(n = 12,166)
Amlodipine/ 
atorvastatin 
switch 
(n = 1139)
Statin add-on 
(n = 3417)
P-value 
between 
matched 
cohorts
    Pre-index amlodipine adherence 
(PDC  0.80)
– – 597 (52.4) 2439 (71.4) 0.001
  Pre-index amlodipine PDC – – 0.73 ± 0.3 0.83 ± 0.21 0.001
    Days between first pre-index  
amlodipine script and index date
– – 258.5 ± 110.0 236.7 ± 124.7 0.001
aAttribute used in patient matching; bPrimary prevention = patients without a history of heart failure, myocardial infarction, angina, other ischemic heart disease, stroke, or a 
revascularization or endarterectomy procedure; cWith or without chronic kidney disease.
Notes: Data are mean ± standard deviation or n (%), unless otherwise indicated.
Abbreviations: Ah, antihypertensive; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; PDC, proportion of days covered.Patient Preference and Adherence 2009:3 270
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after adjusting for pre-index amlodipine adherence and for 
any amlodipine or statin use during the study. Persistence 
with statin therapy was also significantly longer for patients 
who switched to amlodipine/atorvastatin compared with 
those in the statin add-on cohort.
These observations are in agreement with an earlier study 
demonstrating that patients who were previously naïve to both 
antihypertensive and statin therapy were more likely to be 
adherent and persistent with single-pill amlodipine/atorvastatin 
than with a calcium channel blocker and statin prescribed as 
two separate pills (including coadministered amlodipine and 
atorvastatin).29 Furthermore, our data are in line with studies 
demonstrating that an increase in the number of medications 
or dosing frequency is inversely related to adherence,21,37–40 and 
with previous analyses suggesting that the use of single-pill 
combination agents helps improve medication adherence 
in patients with chronic conditions such as tuberculosis, 
HIV, and diabetes, as well as hypertension.17,22,41 However, 
it should be noted that the relationship between adherence 
and number of pills is not necessarily linear, and some studies 
have conversely shown that being prescribed a higher number 
of pills is associated with greater adherence.42,43 A potential 
explanation for this is that patients on the highest numbers of 
medications are often those with more serious or treatment-
resistant conditions, and a greater overall severity of illness 
may be associated with better adherence.44
Other potential reasons for the adherence benefits of 
single-pill amlodipine/atorvastatin, observed in both the current 
analysis and our previous study,29 include the synchronization 
of antihypertensive and statin therapy initiation,25 and the lower 
number of copayments associated with the single-pill vs two 
pills, both of which have been shown to influence adherence in 
previous analyses.45–48 Interestingly, the proportion of patients 
adherent with pre-index amlodipine was significantly lower 
in the amlodipine/atorvastatin switch cohort than in the statin 
add-on cohort, which raises the possibility that physicians 
already recognize some of these potential adherence benefits 
with single-pill amlodipine/atorvastatin and preferentially 
select patients with poor adherence to start on the single-pill 
formulation.
Some of the improvement in statin adherence conferred 
by switching from amlodipine to single-pill amlodipine/
atorvastatin vs adding a separate statin in this study may result 
from altering patients’ perception of their statin therapy. 
Previous investigations have demonstrated that adherence 
with statin therapy is generally poor,16,34,36,49 and that statin 
adherence is lower than adherence with antihypertensives.21 
Several possible factors may be responsible for patients’ 
apparent reluctance to take statin therapy as prescribed; most 
likely this is due to a combination of concerns over potential 
adverse events and a perceived lack of therapeutic benefit.50,51 
Additionally, the BP-lowering benefits of antihypertensive 
drugs can be more immediately monitored, which may 
help reinforce patients’ awareness of the therapeutic 
benefits of their antihypertensive medications. In particular, 
self-monitoring of BP using home-monitoring has been 
associated with improved adherence with therapy.52,53 
In contrast, such immediate feedback cannot be provided 
for lipid-lowering therapy, which may limit the perceived 
benefit for the patient.
Table 2 Adherence patterns by index regimen at 180-days follow-up
Characteristic Amlodipine/
atorvastatin switch 
(n = 1139)
Statin add-on 
(n = 3417)
P-valuea
  number of post-index medication prescriptions 3.76 ± 1.99 3.44 ± 1.99 0.001
Among all patients
  Post-index adherence (PDC  0.80) 579 (50.8) 1514 (44.3) 0.001
  Post-index adherence, PDC 0.70 ± 0.28 0.65 ± 0.29 0.001
  Days supply post-index 125.6 ± 50.1 117.2 ± 52.8 0.001
  Persistence, days 127.6 ± 61.7 116.9 ± 63.4 0.001
Among patients with 2+ prescriptions
  number of patients 958 (84.1) 2715 (79.5)
  Post-index adherence, PDC 0.78 ± 0.21 0.75 ± 0.23 0.010
  Days supply post-index 140.7 ± 37.7 135.3 ± 41.4 0.010
  Persistence, days 143.0 ± 53.8 135.0 ± 57.4 0.001
Notes: Data are mean ± standard deviation or n (%). aComparison of amlodipine/atorvastatin vs statin add-on.
Abbreviation: PDC, proportion of days covered.Patient Preference and Adherence 2009:3 271
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Our data support the hypothesis that the use of single-pill 
amlodipine/atorvastatin could help to improve adherence with 
statin therapy by promoting adherence to the levels achieved 
with antihypertensive therapy. For example, the proportion of 
patients adherent with statin therapy at 6 months after initiating 
therapy in this study was 44% in the statin add-on cohort, 
comparable with the proportion of patients adherent with 
statin therapy in our previous analysis (43%);21 in contrast, 
the proportion adherent with statin therapy in the single-pill 
cohort was 51%, which approaches the proportion adherent 
with antihypertensives in our earlier investigation (58%).21
This study should be interpreted in light of some limitations. 
As with any retrospective, non-randomized comparison 
between groups, selection bias may have resulted in more 
adherent patients receiving amlodipine/atorvastatin than statin 
add-on therapy. However, the propensity score matching 
Less likely to achieve adherence More likely to achieve adherence
Multivariate odds ratio (95% confidence interval)
Amlodipine/atorvastatin switch  vs Statin add-on
Pre-index amlodipine PDC: <0.80 vs ≥0.80
Pre-index primary CVD prevention: yes vs no
1.64*
2.95*
0.91
(1.42-1.89)
(2.57-3.37)
(0.78-1.07)
0 1 2 3 4 5 6
Figure 1 Adjusted odds ratio (95% confidence interval) of achieving adherence (proportion of days covered [PDC] 0.80) with statin therapy at 180-day follow-up.
Note: *P  0.001 for group comparison parameter estimate in the regression.
Abbreviation: CVD, cardiovascular disease.
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process enabled adjustment for observable predictors of 
treatment assignment, with the exclusion of patients who could 
not be well matched. In addition, as mentioned above, a higher 
proportion of patients in the statin add-on cohort were adherent 
with amlodipine in the pre-index period, suggesting that in fact 
this cohort might have been expected to be more adherent with 
treatment than the amlodipine/atorvastatin switch cohort.
Prior to propensity score matching, patients in the statin 
add-on group had a higher incidence of comorbidities than 
in the amlodipine/atorvastatin switch group, and some dif-
ferences remained post-matching. For example, a slightly 
higher proportion of patients in the statin add-on group had 
a history of CVD than in the amlodipine/atorvastatin switch 
group, and there were significantly more patients with angina 
and revascularization procedures in the add-on vs the switch 
group. The between-group differences in the proportion of 
patients with cancer or prior MI also approached significance. 
However, the overall severity of illness was similar between 
the matched cohorts. Furthermore, we demonstrated that 
primary CVD prevention status was not a predictor of adher-
ence in this study, and is therefore unlikely to have had a 
substantial impact on the results observed.
An inherent limitation of all claims data analyses is 
reliance on accurate ICD-9-CM coding, leading to the 
potential for under- or over-reporting of certain conditions. 
For example, obesity is often under-coded, and thus accurate 
adjustments for the incidence of obesity or the metabolic 
syndrome between groups were not possible. However, other 
cardiovascular comorbidities and overall severity of illness 
were included as variables in the propensity score matching 
and thus the proportion of patients with such cardiovascular 
risk factors was likely to have been similar between groups. 
In addition, under-coding of hypertension may have led to 
the exclusion of some otherwise eligible patients, but this 
exclusion criterion avoided the inclusion of patients who 
were prescribed amlodipine for the treatment of angina. Other 
limitations include the fact that patients aged  65 years who 
were not enrolled in a Medicare Risk plan were excluded; 
thus the proportion of elderly patients, who are likely to be 
in poorer overall health and taking more concomitant medi-
cations, is likely to be lower in this analysis than in clinical 
practice. Data for the uninsured or patients in long-term care 
settings, such as nursing homes and hospices, were also not 
available in the database, which may limit the generalizability 
of these data to these potentially higher risk populations.
Assessing adherence based on prescription refill rates 
is a proxy measure only, and a patient’s true pattern of 
medication-taking may still be unknown. However, studies 
of the validity of refill rates as an adherence measure have 
shown that refill rates are significantly associated with 
clinical measures of adherence such as serum drug levels.54 
Furthermore, although the primary categorization of adher-
ence based on a PDC  0.80 was arbitrary, this cut point is 
a commonly accepted definition of medication adherence in 
studies using pharmacy refill records.16,19,21,29,34–36 It was not 
possible to assess therapeutic outcomes or adverse events 
Table 3 Adherence by class-level exposure: sensitivity analysis
Characteristic Any amlodipine usea Any statin useb
Amlodipine/
atorvastatin 
switch 
(n = 1139)
Statin add-on 
(n = 3417)
P-value Amlodipine/
atorvastatin 
switch 
(n = 1139)
Statin add-on 
(n = 3417)
P-value
Among all patients
    Post-index adherence (PDC  0.80) 678 (59.5) 1453 (42.5) 0.001 613 (53.8) 1536 (45.0) 0.001
    Post-index adherence, PDC 0.76 ± 0.24 0.64 ± 0.29 0.001 0.72 ± 0.27 0.66 ± 0.29 0.001
    Days supply post-index 137.0 ± 43.7 116.0 ± 51.8 0.001 129.5 ± 48.2 118.1 ± 52.6 0.001
Among patients with  
2+ prescriptions
  number of patients 1053 (92.4) 2770 (81.1) 994 (87.3) 2739 (80.2)
    Post-index adherence, PDC 0.80 ± 0.20 0.75 ± 0.18 0.001 0.79 ± 0.21 0.75 ± 0.23 0.003
  Days supply post-index 144.5 ± 35.4 135.2 ± 32.3 0.001 141.8 ± 37.1 135.7 ± 41.3 0.003
Notes: Data are mean ± standard deviation or n (%). aincludes prescriptions for amlodipine (generic or norvasc® [Pfizer Inc, New  York, NY]), or single-pill amlodipine/atorvastatin 
in either cohort; bincludes prescriptions for any statin or single-pill amlodipine/atorvastatin in either cohort.
Abbreviation: PDC, proportion of days covered.Patient Preference and Adherence 2009:3 273
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in this study due to an inability to cross-reference lab test 
data with prescription claims in this database. Previous 
research has provided evidence that higher adherence 
with antihypertensive and lipid-lowering medications is 
associated with better clinical efficacy and outcomes in 
the long-term;17–20 however, further investigations should 
aim to confirm that the specific adherence benefits of 
amlodipine/atorvastatin translate to improved therapeutic 
efficacy.
As only pre-index variables were included in the 
propensity score matching model, it was not possible to 
adjust for post-index variables such as the use of generic 
vs branded products or copayment costs, both of which 
have previously been suggested to impact on medication 
adherence.55,56 However, as payer and plan type were included 
in the propensity score matching, differences in the use of 
generic products and drug-specific copayment costs would 
be accounted for at the insurance plan level. Moreover, as 
discussed above, the reduced number of copayments with 
single-pill therapy was considered part of the therapeutic 
package affecting adherence in the two study groups, and 
was therefore not adjusted for in these analyses.
Given the potential influence on adherence of using 
generic vs branded products,55,56 it should also be noted that 
patent protection on amlodipine ended in September 2007 
and that subsequently generic amlodipine has been widely 
available. As this fell outside of the study period for this 
analysis (July 1, 2004 to June 30, 2007), this would not have 
influenced the results of our study. However, the availability 
of generic amlodipine in current clinical practice should be 
considered in future analyses and when interpreting these 
results.
Despite the limitations of this study, the data presented 
provide evidence that the use of single-pill amlodipine/
atorvastatin combination therapy to integrate statin therapy 
with ongoing antihypertensive treatment helps to improve 
adherence with lipid-lowering therapy to the levels of adher-
ence observed with antihypertensives. By switching new 
statin user from their existing amlodipine therapy to single-
pill amlodipine/atorvastatin, it is possible that patients main-
tain positive perceptions of their antihypertensive therapy, 
and that this, in combination with reduced pill burden and the 
synchronization of therapy, contributes to greater adherence 
compared with adding a separate statin.
Conclusion
Single-pill amlodipine/atorvastatin combination therapy 
has the potential to improve adherence with statin therapy, 
perhaps by conferring the greater level of adherence 
observed with antihypertensives such as amlodipine. When 
adding statin therapy in patients with hypertension who are 
already receiving amlodipine, clinicians should consider 
the potential benefits to therapy adherence afforded by 
single-pill amlodipine/atorvastatin.
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